Nano-Biotix invest or not invest

By: Dan Morris.A c c o m p a n i e d b y A l l i s o n H u n t

What are they?

•NanoBiotix is a Nano medicine corporation based in Paris.

• they are Developing revolutionary ways to treat local cancer by developing the nanox-ray to enhance effective radiological therapy.

•Their main competitor is Aveo Oncology formerly Aveo Pharmaceuticals

N a n o b i o t i x h a s r e c e i v e d a p p r o v a l f r o m t h e F r e n c h N a t i o n a l S e c u r i t y A g e n c y f o r M e d i c i n e s a n d H e a l t h P r o d u c t s t o s t a r t t h e i r P h a s e I I / I I I r e g i s t r a t i o n t r i a l i n O c t o b e r 2 0 1 4 .

H a s a l i c e n s i n g c o n t r a c t w i t h P h a r m a E n g i n e , I n c . f o r t h e d e v e l o p m e n t o f N B T X R .

W a s f o u n d e d i n 2 0 0 3 a n d i s b a s e d i n P a r i s , F r a n c e .

N a n o b i o t i x S A w i l l b e a d d e d t o t h e E u r o n e x t 1 5 0 I n d e x .

N a n o b i o t i x h a s 4 0 e m p l o y e e s .

What are they?

•NanoBiotix is a Nano medicine corporation based in Paris.

• they are Developing revolutionary ways to treat local cancer by developing the nanox-ray to enhance effective radiological therapy.

•Their main competitor is Aveo Oncology formerly Aveo Pharmaceuticals

Aveo Oncology

•It’s a Drug company specializing in Specific treatment options for different patience in what they call Next gen therapeutics.

• from my understanding it seems as though it is more genetic manipulation to cure cancer.

A v e o s p u n o u t o f D a n a - F a r b e r i n

2 0 0 2 a n d s p e n t m o r e t h a n 3 0 0 m t o d e v e l o p t i v o z a n i b a f t e r a c q u i r i n g i t f r o m a J a p a n e s e fi r m .

A v e o P h a r m a c e u t i c a l s t o o k 7 y e a r s t o d e v e l o p a m u c h a n t i c i p a t e d k i d n e y c a n c e r d r u g , w h i c h t h e F D A s h o t d o w n i n l e s s t h a n 4 h o u r s .

A v e o i s r e e l i n g f r o m t h e f a l l o u t a n d h a s s i n c e l e t 1 4 0 e m p l o y e e s g o , 6 2 % o f s t a ff . T h e y h a v e h a d m a n y l a w s u i t s f r o m s h a r e h o l d e r s a g a i n s t t h e m b e c a u s e o f m i s l e a d i n g i n f o r m a t i o n a b o u t t i v o z a n i b . T h e S E C h a s s u b p o e n a e d d o c u m e n t s a s w e l l .

A v e o h a s r e c e n t l y t e r m i n a t e d a l e a s e a n d r e c e i v e d a 1 0 m l o a n w i t h t h i s t h e y f e e l t h e y w i l l h a v e t h e fi n a n c i a l m e a n s t o k e e p r e s e a r c h g o i n g . T h e y h a v e i s s u e d a w a r r a n t t o p u r c h a s e a n a g g r e g a t e o f

Aveo Oncology

•It’s a Drug company specializing in Specific treatment options for different patience in what they call Next gen therapeutics.

• from my understanding it seems as though it is more genetic manipulation to cure cancer.

Investment Valuation ratios

•Nanobiotix•EPS:

–2013: (.69)

–2012: (.59)

–2011: (.46)

•P/E Ratio

–2013: (8.78)

–2012: (11.35)

–2011: 0%

•Market Capitalization

–2013: 248560653.85

–2012: 60,266,500

–2011: 0

•Aveo•EPS

–2013: (.21)

–2012: (2.63)

–2011: .77

•P/E Ratio

–2013: (9.47)

–2012: 2.73

–2011: 1.18

•Market Cap

–2013: 101,350,700

–2012: 60,266,500

–2011: 36,145,200

Liquidity

•NanoBiotix•Current Ratio

–2013: 2.10

–2012: 6.27

–2011: 1.65

•Quick Ratio(acid test)

–2013:2.10

–2012:6.27

–2011: 1.65

•Cash Ratio

–2013: 1.52

–2012: 5.72

–2011: .64

•Aveo•Current Ratio

–2013 410%

–2012 487%

–2011 677%

•Quick Ratio (acid test)

–2013 N/A

–2012 N/A

–2011 N/A

•Cash Ratio

–2013 379%

–2012 410%

–2011 639%

Debt

•Nanobiotix•Debt Ratio

–2013: 11.7%

–2012: 7.6%

–2011: 1.8%

•Debt to Equity

–2013: 27%

–2012: 10%

–2011: 56%

•AVEO•Debt Ratio

–2013: 6%

–2012: 9%

–2011: 52%

•Debt to Equity

–2013: 12%

–2012: 16%

–2011: 6%

Efficiency

•Nanobiotix•Total asset turnover

–2013: 1.6

–2012: .9

–2011: N/A

•Fixed asset turn over

–2013: .39

–2012: 17.8

–2011: 0

•Aveo

•Total asset turnover

–2013: .007 times

–2012: .87 times

–2011: .09 times

•Fixed asset Turnover

–2013: .09

–2012: 149

–2011: 300.03